Today: 28 June 2026
Hang Seng slips as tech drags again, while chip and AI names buck the trend in Hong Kong

Hang Seng slips as tech drags again, while chip and AI names buck the trend in Hong Kong

Hong Kong, Jan 16, 2026, 16:47 HKT

  • Hang Seng slipped 0.29%, erasing earlier gains as big tech stocks showed mixed results
  • Shares tied to chips rose, but shipping, casino, and healthcare stocks dragged the market down
  • Ctrip’s shares dropped 19% the previous day, rattling investors amid an ongoing China antitrust investigation

Hong Kong stocks edged down Friday, slipping after an initial bounce. Drops among big internet players and cyclical sectors weighed on the market, even as semiconductor and AI-related stocks showed gains.

The shifts are significant as investors juggle two competing factors: new regulatory risks in China’s consumer internet sector and a surge of capital flowing into chips and AI companies. Hong Kong finds itself caught in the middle, serving as a key listing venue for both areas.

The Hang Seng slipped 71 points by midday, with mainland investors offloading around HK$600 million via Stock Connect, the channel that allows mainland funds to trade certain Hong Kong shares, according to Ming Pao.

At the close, the Hang Seng Index was down 0.29%, while the Hang Seng Tech Index edged lower by 0.11%. The Hang Seng China Enterprises Index, which tracks key mainland companies listed in Hong Kong, fell 0.50%, according to Futu data.

Xiaomi slipped 2.01% among the big internet names, with Kuaishou down 1.51% and JD.com off 1.30%. NetEase managed a 1.03% gain, Alibaba added 0.97%, and Tencent edged lower by 0.72%.

Chip and hardware stocks saw demand, with Hua Hong Semiconductor jumping 7.39% and Semiconductor Manufacturing International Corp gaining 2.39%, as investors focused on sectors linked to the computing infrastructure expansion.

Smaller AI-related stocks saw gains. MiniMax-WP surged over 22%, and Zhipu climbed close to 4%, according to Futu.

Internet healthcare shares and transport stocks dragged lower. Dingdang Health plunged 11.38%, with Orient Overseas down 4.98% and COSCO Shipping Holdings slipping 3.35%, Futu data showed.

The Hang Seng slipped 0.28% on Jan. 15, still feeling the impact from Thursday’s trading. Ctrip Group-S plunged 19.23% after China’s market regulator launched an investigation into possible abuse of market dominance under the anti-monopoly law, according to Investing.com. JPMorgan warned the stock may face continued downside as investors weigh potential fines and prolonged uncertainty.

Tianfeng Securities noted in a recent report that Hong Kong stocks have laid the groundwork for a rebound, supported by valuation adjustments and improved sentiment. However, they cautioned that gains might be limited as long as overseas interest rates remain elevated and expectations for rate cuts stay subdued.

A major concern is regulatory attention expanding beyond just one firm. Should the Ctrip investigation escalate into a broader crackdown, it might spook investors away from platform and consumer stocks right as money starts flowing back into the sector. Rising global interest rates and dilution from discounted share placements could also weigh heavily if risk appetite fades once more.

Shan Ahmed Khan is a senior markets reporter at TS2.tech, specializing in stocks, technology and macroeconomic trends. A graduate of the Lahore University of Management Sciences (LUMS), he previously worked in investment research and market analysis. His coverage helps readers understand the key developments influencing global financial markets and emerging industries.

Stock Market Today

  • Avino Silver & Gold Mines (TSX:ASM) Stock Review After Pullback and Valuation Analysis
    June 28, 2026, 11:02 AM EDT. Avino Silver & Gold Mines (TSX:ASM) shares have declined 4% in the past week and 13.4% over the last month, despite rising 8.1% year-to-date and 86.2% over the past year. The stock's volatility reflects its exposure to the precious metals sector amid broader materials market fluctuations. Simply Wall St's valuation rates Avino at 2 out of 6, signaling caution. However, a Discounted Cash Flow (DCF) analysis, projecting free cash flows through 2035, estimates an intrinsic value of $13.43 per share, suggesting the stock is undervalued by about 34.7%. Investors should weigh these conflicting valuation signals when considering Avino's potential. The company's recent financial performance and sector dynamics remain key factors in its outlook.

Latest articles

Intel (NASDAQ:INTC) edges lower, pulling back from $700 billion mark

Intel (NASDAQ:INTC) edges lower, pulling back from $700 billion mark

28 June 2026
Intel shares plunged 9.3% from Monday’s 52-week high, erasing $66 billion in market value and falling back below the $700 billion threshold as chip stocks tumbled on AI spending worries, with trading volume far outpacing short interest and sector profitability questions intensifying.
Ondas (NASDAQ:ONDS) drops 15% in volatile week after resale filing

Ondas (NASDAQ:ONDS) drops 15% in volatile week after resale filing

28 June 2026
Ondas Inc. (NASDAQ:ONDS) plunged 15.5% last week to $7.83 despite joining the Russell 3000 Index and announcing $40M+ in new defense orders; a June 26 filing registered 3.38M acquisition shares for resale, equal to 0.64% of shares, setting up a key test of real demand versus supply as index-driven volume fades ahead of the July 3 market holiday.
NVDA selloff drags $74 billion equity stake into spotlight

NVDA selloff drags $74 billion equity stake into spotlight

28 June 2026
Nvidia plunged 8.6% last week to $192.53, wiping out about $443 billion in equity value, as chip stocks suffered their worst week since April and Nvidia’s massive equity investment book added new risk to quarterly results; a further drop to $189.23 would mark a 20% slide from its May high.
Bitcoin price nears $97,000 as ETF inflows rebound and Senate crypto bill stalls
Previous Story

Bitcoin price nears $97,000 as ETF inflows rebound and Senate crypto bill stalls

Merck stock slips as FDA fast-track questions build and earnings near
Next Story

Merck stock slips as FDA fast-track questions build and earnings near

Go toTop